|
|
Affymax receives $10M milestone payment from Takeda - Bizjournals.com |
Bizjournals.com
The Palo Alto-based biopharmaceutical company Affymax (NASDAQ:AFFY) has developed an investigational drug called peginesatide, previously known as Hematide, to treat anemia in dialysis patients with chronic kidney disease. It received the milestone ...
Affymax(R) Receives $10 Million Milestone Payment for FDA Filing of New Drug
|
|
|
Leading Dialysis Team Partners with Global Private Equity Firm - PR Newswire (press release) |
PR Newswire (press release)
10, 2011 /PRNewswire/ -- American Dialysis Corporation, led by Thomas K. Langbein, the former Chairman of Dialysis Corporation of America (DCAI), and several senior management executives, is partnering with Jefferies Capital Partners, a leading private
|
|
NCCPA Launches CAQ Program for PAs in 5 Specialties - HealthLeaders Media |
HealthLeaders Media
... Assistants (NCCPA) has launched a certificate of added qualifications (CAQ) program for certified physician assistants (PA) practicing in cardiovascular and thoracic surgery, emergency medicine, nephrology, orthopedic surgery, and psychiatry.
|
|
Younger Blacks fare relatively worse on dialysis. |
|
U.S. News and World Report: Overall, the data showed that blacks did somewhat better on dialysis than whites: 63.5 percent of whites died during treatment compared with 57.1 percent of blacks. However, when the researchers stratified the results by age, they found surprising differences. For blacks aged 18 to 30, the risk of death was about double -- about 28 percent vs. 14 percent for whites. In the 31-to-40 age group, blacks were 1.5 times more likely to die. Between the ages of 41 and 50, the increased risk of death narrowed to about 45 percent vs. 38 percent.
|
|
Soy tablets of no benefit in preventing bone loss in postmenopausal women. |
|
EurekAlert: A total of 248 women were eligible for the study; 126 were randomized to the group receiving placebo tablets and 122 were randomized to the soy isoflavone group, who received 200 mg of soy isoflavone tablets daily. During two years of follow-up, no significant differences were found between women in the soy isoflavone group and placebo group regarding changes in bone mineral density of the spine (-2 percent vs. -2.3 percent), the total hip (-1.2 percent vs. -1.4 percent) or the femoral neck (-2.2 percent vs. -2.1 percent), respectively.
|
|
|
|
|
<< Start < Prev 751 752 753 754 755 756 757 758 759 760 Next > End >>
|
|
Page 756 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
